Perspectum develops software that enhances standard MRI machines to capture multiparametric mapping data and uses AI to measure organ inflammation and aid diagnosis and monitoring. Its flagship product, LiverMultiScan, has had coverage for roughly 77 million U.S. adults since early 2021 and has been adopted by several major U.S. hospitals. The company also offers FDA-approved MRCP+ technology and is building a platform-based product portfolio for clinical research and clinical use. Perspectum plans to expand its footprint across the U.S. and scale operations to meet growing demand for organ-health assessment. The new funding will be used to scale U.S. operations and accelerate the product pipeline for multiorgan conditions and oncology. Perspectum maintains offices in the U.S., the U.K., Portugal, and Singapore. Perspectum builds software that augments standard MRI machines to capture multiparametric mapping data and uses AI to measure organ inflammation, offering non-invasive alternatives to biopsy. Its flagship product, LiverMultiScan, assesses and monitors chronic liver disease. Since the beginning of 2021, 77 million US adults covered by Medicare and commercial plans have had access to LiverMultiScan. The company has established reimbursement codes and adoption by several major US hospitals and announced a collaboration with Nuance (a Microsoft company) in December 2022. Perspectum plans to scale its US operations, grow its customer base, and accelerate its product pipeline for multiorgan inflammatory conditions and oncology using the new funding. The company has offices in the US, the UK, Portugal, and Singapore. Perspectum develops non-invasive medical imaging software, including LiverMultiScan, which extracts quantitative data from routine MRI scans to aid detection and monitoring of chronic liver disease. LiverMultiScan is FDA-cleared and described in the article as having proven accuracy and precision in assessing liver tissue. The company also operates an imaging-focused CRO that supports biopharmaceutical companies developing assets in liver and metabolic diseases. The $36M financing announced will be used to commercialize LiverMultiScan for clinical use, expand the CRO business, and develop additional products targeting biliary disease, diabetes and cancer for both clinical and CRO applications. Perspectum is actively evaluating its technology in China and is positioned to support drug development and clinical deployment as new NASH therapies approach approval. The company emphasizes precision medicine using advanced imaging and genetics to enable early detection, diagnosis, and targeted treatment.

Total raised

$91M

Funding rounds

3

Latest round

Series C

Latest activity

Mar 2023